New pill targets Hard-to-Treat cancers with unique genetic flaw

NCT ID NCT06004245

Recruiting now Disease control Sponsor: Vividion Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 27 times

Summary

This early-stage study tests an experimental pill, VVD-133214, in people with advanced solid tumors that have a specific genetic feature (MSI or dMMR). The drug aims to block a protein that helps these cancers grow. The study will check safety and whether the drug shrinks tumors, both alone and combined with other cancer medicines.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Alfred Hospital
ACTIVE_NOT_RECRUITING

Melbourne, Victoria, 3181, Australia
Asan Medical Center
ACTIVE_NOT_RECRUITING

Seoul, 05505, South Korea
BCCA-Vancouver Cancer Centre
COMPLETED

Vancouver, British Columbia, V5Z 4E6, Canada
CLCC Leon Berard Lyon
COMPLETED

Lyon, 69008, France
City of Hope Cancer Center
RECRUITING

Duarte, California, 91010, United States
City of Hope at Irvine Lennar
RECRUITING

Irvine, California, 91355, United States
Clinica Universidad de Navarra Madrid
ACTIVE_NOT_RECRUITING

Madrid, Madrid, 28027, Spain
Clinica Universitaria de Navarra
ACTIVE_NOT_RECRUITING

Pamplona, Navarre, 31008, Spain
Duke University
COMPLETED

Durham, North Carolina, 27705, United States
Emory University School of Medicine
RECRUITING

Atlanta, Georgia, 30322, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Gustave Roussy
ACTIVE_NOT_RECRUITING

Villejuif, 94805, France
Hospital Clinico Universitario de Valencia
ACTIVE_NOT_RECRUITING

Valencia, Valencia, 46010, Spain
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Norton Cancer Institute - MDC
ACTIVE_NOT_RECRUITING

Louisville, Kentucky, 40202, United States
Oklahoma University Health Sciences Center
ACTIVE_NOT_RECRUITING

Oklahoma City, Oklahoma, 73170, United States
Princess Margaret Cancer Center
ACTIVE_NOT_RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Rigshospitalet
ACTIVE_NOT_RECRUITING

København Ø, 2100, Denmark
Royal Marsden Hospital (Sutton)
ACTIVE_NOT_RECRUITING

Sutton, SM2 5PT, United Kingdom
Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08901, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
SCRI Oncology Partners
ACTIVE_NOT_RECRUITING

Nashville, Tennessee, 37203, United States
START Madrid. Centro Integral Oncologico Clara Campal
ACTIVE_NOT_RECRUITING

Madrid, Madrid, 28050, Spain
Sarah Cannon Research Institute
ACTIVE_NOT_RECRUITING

London, W1G 6AD, United Kingdom
Sarawak Public Hospital
ACTIVE_NOT_RECRUITING

Kuching, Sarawak, 93586, Malaysia
Seoul National University Bundang Hospital
ACTIVE_NOT_RECRUITING

Seongnam-si, 13620, South Korea
Seoul National University Hospital
ACTIVE_NOT_RECRUITING

Seoul, 03080, South Korea
St Vincents Sydney
ACTIVE_NOT_RECRUITING

Darlinghurst, New South Wales, 2010, Australia
The Christie
ACTIVE_NOT_RECRUITING

Manchester, M20 4BX, United Kingdom
UZ Leuven Gasthuisberg
ACTIVE_NOT_RECRUITING

Leuven, 3000, Belgium
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
ACTIVE_NOT_RECRUITING

Barcelona, BARCELONA, 08035, Spain

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS ADVANCED SOLID TUMORS COLORECTAL CANCER